Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.
China: A recent randomized clinical trial has highlighted the potential benefits of intraoperative esketamine in reducing ...
IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...
The American Psychiatric Association (APA) named Mark Rapaport, MD, of the University of Utah, as the medical society's next ...
Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).
The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
In reality, most people living on the street are not uniquely immune to mental health interventions — they are uniquely ...
It is now approved for adults with treatment-resistant depression (TRD) who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster ...
Bryan Johnson injected himself with ketamine, a hallucinogen favored by Elon Musk, for 15 days. He used a helmet from his ...
Intraoperative esketamine infusion significantly reduced the incidence of postpartum depression (PPD) at 6 weeks post partum ...